Table 1– Patient demographics and baseline characteristics (intent-to-treat population).
| FF/VI 200/25 μg once daily | FF 200 μg once daily | FP 500 μg twice daily | Total | |
| Subjects | 197 | 194 | 195 | 586 |
| Age years | 46.6±15.05 | 44.6±14.33 | 47.3±14.06 | 46.2±14.51 |
| Females | 116 (59) | 113 (58) | 116 (59) | 345 (59) |
| Duration of asthma years | 17.01±13.227 | 14.71±11.920 | 14.85±12.533 | 15.53±12.597 |
| Baseline pre-bronchodilator FEV1 L | 2.129±0.6539 | 2.190±0.6756 | 2.138±0.6725 | 2.153±0.6668 |
| Baseline FEV1 % predicted | 66.59±12.614 | 66.66±12.388 | 67.57±12.185 | 66.94±12.383 |
| Screening reversibility FEV1 % | 29.58±19.828 | 29.17±17.035 | 29.56±16.375 | 29.44±17.790 |
| Screening absolute reversibility FEV1 mL | 561.7±367.91 | 583.3±346.30 | 568.0±313.08 | 570.9±342.77 |
| Baseline rescue-free 24-h periods % | 7.6±19.22 | 7.8±20.68 | 6.3±18.03 | |
| Baseline symptom-free 24-h periods % | 5.1±15.20 | 4.7±16.06 | 2.7±9.83 | |
| Pre-study ICS regimen | ||||
| ICS alone | 47 (24) | 44 (23) | 49 (25) | 140 (24) |
| ICS + salmeterol | 106 (54) | 102 (53) | 98 (50) | 306 (52) |
| ICS + formoterol | 44 (22) | 48 (25) | 48 (25) | 140 (24) |
Data are presented as n, mean±sd or n (%). FF: fluticasone furoate; VI: vilanterol; FP: fluticasone propionate; FEV1: forced expiratory volume in 1 s; ICS: inhaled corticosteroid.